Home Angiogenesis Src inhibitor - Bcr-Abl inhibitor - c-Kit inhibitor - Autophagy activator - Apoptosis related activator Dasatinib For research use only.

Dasatinib

Synonyms: BMS-354825

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.

Dasatinib Chemical Structure

Dasatinib Chemical Structure

CAS: 302962-49-8

Selleck's Dasatinib has been cited by 554 publications

Purity & Quality Control

Batch: Purity: 99.99%
99.99

Products often used together with Dasatinib

Olaparib (AZD2281)

Dasatinib and Olaparib combination induce cell-cycle arrest and demonstrates strong induction of apoptosis in a caspase‐dependent manner in MDA‐MB‐231/HS‐578T cells.

Corrales-Sanchez V, et al. J Cell Mol Med. 2020 Mar;24(5):3117-3127.

Fisetin

Dasatinib and Fisetin induce apoptosis in senescent cells, produce health benefits, and extend lifespan in animal models.

Martel J, et al. Med Res Rev. 2020 Nov;40(6):2114-2131.

Trametinib (GSK1120212)

Dasatinib and Quercetin treatment exacerbates obesity- and age-dependent liver disease progression.

Blagosklonny MV, et al. Oncotarget. 2021 Aug 31; 12(18): 1821–1835.

Imatinib

Dasatinib demonstrates superior results in Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) treatment compared with Imatinib.

Shen S, et al. JAMA Oncol. 2020 Mar 1;6(3):358-366.

Nilotinib

Dasatinib and Nilotinib are tyrosine kinase inhibitors (TKIs) used as first-line treatments for philadelphia chromosome-positive chronic myeloid leukemia (CML).

Miura M, et al. Biol Pharm Bull. 2015;38(5):645-54.

Other Src Products

Related compound libraries

Choose Selective Src Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 Growth Inhibition Assay 72 h DMSO IC50=0.00007 μM 17956080
K562 Growth Inhibition Assay 72 h DMSO IC50=0.001 μM 17956080
M07e Growth Inhibition Assay 72 h DMSO IC50=0.0012 μM 17956080
ALL3 Cytotoxic Assay 0.1μM 72 h DMSO IC50=0.0004 μM 19889540
CML Growth Inhibition Assay 20 min DMSO IC50=0.001 μM 19219016
BA/F3 Growth Inhibition Assay 72 h DMSO IC50=6.589 μM 23088644
BA/F3 Growth Inhibition Assay 72 h DMSO Induces antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M351T mutant with IC50 of 0.00083μM 23088644
BA/F3 Growth Inhibition Assay 72 h DMSO Induces antiproliferative activity against mouse BA/F3 cells expressing wild type Bcr-Abl with IC50 of 0.0045μM 23088644
BA/F3 Growth Inhibition Assay 72 h DMSO Induces antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant with IC50 of 1.714μM 23088644
BA/F3 Growth Inhibition Assay 72 h DMSO Induces cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F486S mutant assessed as growth Inhibition with IC50 of 0.0009μM 23301703
BA/F3 Growth Inhibition Assay 72 h DMSO Induces cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255K mutant assessed as growth Inhibition with IC50 of 0.0032μM 23301703
BA/F3 Growth Inhibition Assay 72 h DMSO Induces cytotoxicity against mouse BA/F3 cells expressing BCR-ABL G250E mutant assessed as growth Inhibition with IC50 of 0.0051μM 23301703
BA/F3 Growth Inhibition Assay 72 h DMSO Induces cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Q252H mutant assessed as growth Inhibition with IC50 of 0.008μM 23301703
BA/F3 Growth Inhibition Assay 72 h DMSO Induces cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E359V mutant assessed as growth Inhibition with IC50 of 0.0013μM 23301703
BA/F3 Growth Inhibition Assay 72 h DMSO Induces cytotoxicity against mouse BA/F3 cells expressing wild type BCR-ABL assessed as growth Inhibition with IC50 of 0.0019μM 23301703
BA/F3 Growth Inhibition Assay 72 h DMSO Induces cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253H mutant assessed as growth Inhibition with IC50 of 0.0023μM 23301703
BA/F3 Growth Inhibition Assay 72 h DMSO Induces cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant assessed as growth Inhibition with IC50 of 3.6μM 23301703
BA/F3 Growth Inhibition Assay 72 h DMSO Induces cytotoxicity against mouse BA/F3 cells assessed as growth Inhibition with IC50 of 2.5μM 23301703
T cell Growth Inhibition Assay 72 h DMSO Inhibits anti CD3- and anti CD28-induced T cell proliferation with IC50 of 0.003μM 17154512
WiDr Growth Inhibition Assay 72 h DMSO IC50=0.052 μM 15615512
PC3 Growth Inhibition Assay 72 h DMSO IC50=0.0094 μM 15615512
MDA-MB-231 Growth Inhibition Assay 72 h DMSO IC50=0.012 μM 15615512
Hs578T Cytotoxic Assay 72 h DMSO GI50=0.03 μM 24015327
HMEC Cytotoxic Assay 72 h DMSO GI50=1.8 μM 24015327
DU145 Cytotoxic Assay 72 h DMSO GI50=0.16 μM 24015327
U251 Cytotoxic Assay 72 h DMSO GI50=2.81 μM 24015327
NCI60 Cytotoxic Assay 72 h DMSO GI50=5.7 μM 24015327
MALME-3M Cytotoxic Assay 72 h DMSO GI50=6.61 μM 24015327
KM12 Cytotoxic Assay 72 h DMSO GI50=7.44 μM 24015327
SW620 Cytotoxic Assay 72 h DMSO GI50=8.43 μM 24015327
RXF 393NL Cytotoxic Assay 4 days DMSO IC50=0.0217 μM 23253074
LXFA 983L Cytotoxic Assay 4 days DMSO IC50=0.0565 μM 23253074
PRXF DU145 Cytotoxic Assay 4 days DMSO IC50=0.0623 μM 23253074
PAXF 1657L Cytotoxic Assay 4 days DMSO IC50=0.121 μM 23253074
CXF 1103L Cytotoxic Assay 4 days DMSO IC50=4.36 μM 23253074
GXF251L Cytotoxic Assay 4 days DMSO IC50=2.25 μM 23253074
NCI-H23 Growth Inhibition Assay 72 h DMSO IC50=2.27 μM 23521020
HCT116 Growth Inhibition Assay 72 h DMSO IC50=2.3 μM 23521020
MCF7 Growth Inhibition Assay 72 h DMSO IC50=2.57 μM 23521020
NCI-H460 Growth Inhibition Assay 72 h DMSO IC50=8.99 μM 23521020
DLD1 Growth Inhibition Assay 72 h DMSO IC50=4.6 μM 23567960
NCI-H661 Growth Inhibition Assay 72 h DMSO IC50=7.8 μM 23567960
A549 Growth Inhibition Assay 72 h DMSO IC50=8.2 μM 23567960
U937 Growth Inhibition Assay 72 h DMSO IC50=12.2 μM 23567960
HEK293 Function Assay 10 μM DMSO Induces binding affinity to human full-length His-tagged Myt1 kinase expressed in HEK293 cells with IC50 of 0.063μM 22770610
HUVEC Growth Inhibition Assay 0.15 μM 72 h DMSO Induces antiangiogenic activity in HUVEC co-cultured with vascular smooth muscle cells assessed as Inhibition of cell growth at 0.15 uM 22853993
HUVEC Function Assay 15 μM 72 h DMSO Induces antiangiogenic activity in HUVEC co-cultured with vascular smooth muscle cells assessed as Inhibition of network formation at 1.8 to 15 uM 22853993
Plasmodium falciparum Function Assay 10 μM 15 min DMSO Inhibits Plasmodium falciparum proliferation by inhibiting the Function of PfCDPK1 protein with IC50 of 1.17μM 24550330
PC3 Function Assay 0.1 μM 5 h DMSO Inhibits human PC3 cell adhesion at 100 nM 19462975
DU145 Function Assay 0.1 μM 5 h DMSO Inhibits human DU145 cell adhesion at 100 nM 19462975
PC3 Kinase Assay 0.1 μM 5 h DMSO Inhibits cSrc in human PC3 cells assessed as reduction of phosphorylated Src Y416 level at 100 nM 19462975
DU145 Kinase Assay 0.1 μM 5 h DMSO Inhibits cSrc in human DU145 cells assessed as reduction of phosphorylated Src Y416 level at 100 nM 19462975
PC3 Kinase Assay 0.1 μM 5 h DMSO Inhibits cSrc in human PC3 cells assessed as reduction of phosphorylated FAK Y576/Y577 level at 100 nM 19462975
DU145 Kinase Assay 0.1 μM 5 h DMSO Inhibits cSrc in human DU145 cells assessed as reduction of phosphorylated FAK Y576/Y577 level at 100 nM 19462975
Huh7 Antiviral Assay 2.5 μM 4 days DMSO Inhibits viral spread in Dengue virus-infected human Huh7 cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM 17360676
C6/36 Antiviral Assay 2.5 μM 4 days DMSO Inhibits viral spread in Dengue virus-infected asian tiger mosquito C6/36 cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM 17360676
U937 Function Assay 1 μM 1 h DMSO Reduces basal TNFalpha release in human U937 cells 17684099
U937 Function Assay 1 μM 1 h DMSO Reduces LPS-induced TNFalpha release in human U937 cells 17684099
murine mast cell Function Assay 1 μM 24 h DMSO Inhibits antigen-induced IL6 secretion in IgE primed mouse mast cells at 1 uM 17684099
FDC-P1 Function assay 48 hrs IC50 = 0.0074 μM 20156689
K562 Cytotoxicity assay 72 hrs IC50 = 12.83 μM 22217877
U937 Cytotoxicity assay 72 hrs IC50 = 13.63 μM 22217877
Sf21 Function assay 5 mins IC50 = 10 μM 22961681
Ba/F3 Function assay 1 hr Inhibition of Bcr-Abl T315I mutant (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction of phosphorylated STAT5 level after 1 hr by Western blot analysis 23600806
Ba/F3 Function assay 1 hr Inhibition of Bcr-Abl T315I mutant (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction of phosphorylated CrkL level after 1 hr by Western blot analysis 23600806
Ba/F3 Function assay 1 hr Inhibition of Bcr-Abl T315I mutant (unknown origin) phosphorylation transfected in mouse Ba/F3 cells after 1 hr by Western blot analysis 23600806
Sf9 Function assay 15 to 20 mins IC50 = 13.1 μM 23956101
Sf9 Function assay 20 mins IC50 = 27.3 μM 23956101
HMC-1.2 Antiproliferative assay IC50 = 0.82 μM 25004409
RXF 393NL Antiproliferative assay 4 days GI50 = 0.0217 μM 25076195
LXFA 983L Antiproliferative assay 4 days GI50 = 0.0565 μM 25076195
PRXF DU145 Antiproliferative assay 4 days GI50 = 0.0623 μM 25076195
PAXF 1657L Antiproliferative assay 4 days GI50 = 0.121 μM 25076195
GXF251L Antiproliferative assay 4 days GI50 = 2.25 μM 25076195
CXF 1103L Antiproliferative assay 4 days GI50 = 4.36 μM 25076195
SH-SY5Y Apoptosis assay 0.1 uM 24 hrs Induction of apoptosis in human SH-SY5Y cells assessed as accumulation of hypodiploid cells at 0.1 uM after 24 hrs by propidium iodide staining-based cytofluorimetry 25469771
ECRF24 Cytotoxicity assay 72 hrs IC50 = 5.7 μM 25815152
A2780 Cytotoxicity assay 72 hrs IC50 = 8.7 μM 25815152
HEK293 Cytotoxicity assay 72 hrs IC50 = 14.3 μM 25815152
MDA-MB-231 Cytotoxicity assay 72 hrs IC50 = 0.178 μM 25835317
MDA-MB-231 Antiinvasive assay 0.1 uM 24 hrs Antiinvasive activity against human MDA-MB-231 cells at 0.1 uM after 24 hrs by transwell assay 25835317
MDA-MB-231 Cell cycle assay 0.3 uM 24 to 48 hrs Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G0/G1 phase at 0.3 uM after 24 to 48 hrs by flow cytometric analysis 25835317
MDA-MB-231 Function assay >0.03 uM 20 hrs Inhibition of Src in human MDA-MB-231 cells assessed as reduction of FAK phosphorylation at >0.03 uM after 20 hrs by Western blot analysis 25835317
MDA-MB-231 Antimigratory assay 0.03 to 0.3 uM 20 hrs Antimigratory activity against human MDA-MB-231 cells at 0.03 to 0.3 uM after 20 hrs by wound healing assay 25835317
MDA-MB-231 Function assay 0.001 to 1 uM 20 hrs Inhibition of Src phosphorylation in human MDA-MB-231 cells at 0.001 to 1 uM after 20 hrs by Western blot analysis 25835317
MDA-MB-231 Antiproliferative assay >0.01 uM 12 days Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of colony formation at >0.01 uM after 12 days by crystal violet staining-based assay 25835317
MDA-MB-231 Antitumor assay 40 mg/kg/day 18 days Antitumor activity against human MDA-MB-231 cells xenografted in SCID mouse assessed as tumor growth inhibition at 40 mg/kg/day administered for 18 days measured every 3 days during compound dosing 25835317
MDA-MB-231 Cytotoxicity assay 48 hrs IC50 = 1.12 μM 25899332
MCF7 Cytotoxicity assay 48 hrs IC50 = 8.05 μM 25899332
HCC366 Antiproliferative assay 72 hrs IC50 = 0.029 μM 26191369
NCI-H2286 Antiproliferative assay 72 hrs IC50 = 0.032 μM 26191369
K562 Antiproliferative assay 72 hrs IC50 = 0.001 μM 26195136
K562 Cytotoxicity assay IC50 = 0.08 μM 26264503
IR-K562 Cytotoxicity assay IC50 = 1.9 μM 26264503
THP1 Cytotoxicity assay IC50 = 6 μM 26264503
HEK293 Cytotoxicity assay CC50 = 16 μM 26264503
K562 Cytotoxicity assay 48 hrs IC50 = 0.45 μM 26451772
K562 Antiproliferative assay 72 hrs GI50 = 0.0003 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 0.0003 μM 26789553
KU812 Antiproliferative assay 72 hrs GI50 = 0.0003 μM 26789553
MEG01 Antiproliferative assay 72 hrs GI50 = 0.0003 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 0.001 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 0.001 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 0.001 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 0.003 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 0.003 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 0.003 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 0.003 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 0.004 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 0.004 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 0.005 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 0.008 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 0.008 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 0.01 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 0.014 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 0.014 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 0.017 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 0.039 μM 26789553
CHL Antiproliferative assay 72 hrs GI50 = 0.27 μM 26789553
MOLM14 Antiproliferative assay 72 hrs GI50 = 2.3 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 3 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 3 μM 26789553
MV4-11 Antiproliferative assay 72 hrs GI50 = 3.6 μM 26789553
HEL Antiproliferative assay 72 hrs GI50 = 5.3 μM 26789553
BA/F3 Function assay 72 hrs GI50 = 9.94 μM 26789553
KU812 Function assay 0.1 uM 1 hr Inhibition of BCR/ABL in human KU812 cells assessed as downregulation of CrkL phosphorylation at T207 site at 0.1 uM after 1 hr by immunoblotting method 26789553
KU812 Function assay 0.1 uM 1 hr Inhibition of BCR/ABL in human KU812 cells assessed as downregulation of CrkL phosphorylation at T207 site at 0.1 uM after 1 hr by immunoblotting method 26789553
MEG01 Function assay 0.1 uM 1 hr Inhibition of BCR/ABL in human MEG01 cells assessed as downregulation of CrkL phosphorylation at T207 site at 0.1 uM after 1 hr by immunoblotting method 26789553
MEG01 Function assay 0.1 uM 1 hr Inhibition of BCR/ABL in human MEG01 cells assessed as downregulation of CrkL phosphorylation at T207 site at 0.1 uM after 1 hr by immunoblotting method 26789553
K562 Function assay 0.1 uM 1 hr Inhibition of BCR/ABL in human K562 cells assessed as downregulation of CrkL phosphorylation at T207 site at 0.1 uM after 1 hr by immunoblotting method 26789553
K562 Function assay 0.1 uM 1 hr Inhibition of BCR/ABL in human K562 cells assessed as downregulation of CrkL phosphorylation at T207 site at 0.1 uM after 1 hr by immunoblotting method 26789553
K562 Cytotoxicity assay 72 hrs IC50 = 0.00025 μM 26814890
BA/F3 Cytotoxicity assay 72 hrs IC50 = 0.09 μM 26814890
BAF3 Function assay 72 hrs EC50 = 0.00004 μM 27010810
BAF3 Function assay 72 hrs EC50 = 0.00004 μM 27010810
BxPC3 Antiproliferative assay 72 hrs EC50 = 0.033 μM 27010810
MDA-MB-231 Antiproliferative assay 72 hrs EC50 = 0.044 μM 27010810
Caki2 Antiproliferative assay 72 hrs EC50 = 0.055 μM 27010810
NCI-H1975 Antiproliferative assay 72 hrs EC50 = 0.173 μM 27010810
PC3 Antiproliferative assay 72 hrs EC50 = 0.232 μM 27010810
insect Function assay 20 mins IC50 = 0.0005 μM 27115835
MDA-MB-231 Antiproliferative assay 5 days Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 5 days by PrestoBlue assay 27115835
MDA-MB-231 Function assay 3 to 100 nM 1.5 hrs Inhibition of SRC phosphorylation at tyrosine 416 in human MDA-MB-231 cells at 3 to 100 nM preincubated for 1.5 hrs followed by serum stimulation for 1 hr by Western blot analysis 27115835
MDA-MB-231 Function assay 3 to 100 nM 1.5 hrs Inhibition of FAK phosphorylation at tyrosine 861 in human MDA-MB-231 cells at 3 to 100 nM preincubated for 1.5 hrs followed by serum stimulation for 1 hr by Western blot analysis 27115835
MDA-MB-231 Antimigratory assay 10 nM 6 hrs Antimigratory activity in human MDA-MB-231 cells assessed as reduction in cell motility at 10 nM at 6 hrs by microscopy based scratch-wound cell migration assay 27115835
MCF7 Antiproliferative assay 0.03 to 300 uM 5 days Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability at 0.03 to 300 uM after 5 days by PrestoBlue assay 27115835
HCT116 Cytotoxicity assay 96 hrs IC50 = 5.23 μM 27155464
A549 Cytotoxicity assay 96 hrs IC50 = 8.37 μM 27155464
U937 Cytotoxicity assay 96 hrs IC50 = 10.23 μM 27155464
K562 Cytotoxicity assay 96 hrs IC50 = 11.95 μM 27155464
K562 Cytotoxicity assay CC50 = 0.25 μM 27474918
K562 Antiproliferative assay GI50 = 0.001 μM 28435526
K562 Function assay IC50 = 0.000069 μM 29395973
HL60 Function assay IC50 = 0.00011 μM 29395973
KG1a Function assay IC50 = 8.98 μM 29395973
B16-BL6 Function assay 8.13 uM 24 to 48 hrs Inhibition of cell migration of mouse B16-BL6 cells at 8.13 uM incubated for 24 to 48 hrs by cell wound scratch assay 29395973
MCF7 Function assay 7.5 uM 10 days Inhibition of colony formation in human MCF7 cells at 7.5 uM incubated for 10 days by crystal violet staining based plate cloning test 29395973
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) 29435139
Rh30 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells 29435139
HEK293 Function assay 1 hr Ki = 0.0005 μM 29941193
HEK293 Function assay 1 hr IC50 = 0.006 μM 29941193
Ba/F3 Function assay 48 hrs GI50 = 0.00021 μM 30137981
Ba/F3 Function assay 48 hrs GI50 = 0.00025 μM 30137981
Ba/F3 Function assay 48 hrs GI50 = 0.00029 μM 30137981
Ba/F3 Function assay 48 hrs GI50 = 0.0003 μM 30137981
Ba/F3 Function assay 48 hrs GI50 = 0.00033 μM 30137981
Ba/F3 Function assay 48 hrs GI50 = 0.00042 μM 30137981
Ba/F3 Function assay 48 hrs GI50 = 0.00077 μM 30137981
Ba/F3 Function assay 48 hrs GI50 = 0.00098 μM 30137981
Ba/F3 Function assay 48 hrs GI50 = 0.00144 μM 30137981
Ba/F3 Function assay 48 hrs GI50 = 2.562 μM 30137981
Vero qHTS assay Vero cells viability qHTS for Zika virus inhibitors 33229545
HepG2 qHTS assay HepG2 cells viability qHTS for Zika virus inhibitors 33229545
BV-173 Growth Inhibition Assay IC50=0.000000109 μM SANGER
K-562 Growth Inhibition Assay IC50=0.000000266 μM SANGER
BL-70 Growth Inhibition Assay IC50=0.000000822 μM SANGER
EM-2 Growth Inhibition Assay IC50=0.00000108 μM SANGER
LAMA-84 Growth Inhibition Assay IC50=0.00000321 μM SANGER
MEG-01 Growth Inhibition Assay IC50=0.0000098 μM SANGER
EoL-1-cell Growth Inhibition Assay IC50=0.0000131 μM SANGER
CTV-1 Growth Inhibition Assay IC50=0.0000404 μM SANGER
TE-15 Growth Inhibition Assay IC50=0.00589 μM SANGER
NOS-1 Growth Inhibition Assay IC50=0.00613 μM SANGER
D-336MG Growth Inhibition Assay IC50=0.0063 μM SANGER
LB1047-RCC Growth Inhibition Assay IC50=0.00989 μM SANGER
LB996-RCC Growth Inhibition Assay IC50=0.00991 μM SANGER
SW982 Growth Inhibition Assay IC50=0.01115 μM SANGER
TK10 Growth Inhibition Assay IC50=0.01174 μM SANGER
A704 Growth Inhibition Assay IC50=0.01491 μM SANGER
TE-8 Growth Inhibition Assay IC50=0.01576 μM SANGER
DOHH-2 Growth Inhibition Assay IC50=0.01719 μM SANGER
HOP-62 Growth Inhibition Assay IC50=0.01834 μM SANGER
TE-12 Growth Inhibition Assay IC50=0.01861 μM SANGER
KGN Growth Inhibition Assay IC50=0.01942 μM SANGER
NCI-H1648 Growth Inhibition Assay IC50=0.02011 μM SANGER
OS-RC-2 Growth Inhibition Assay IC50=0.0203 μM SANGER
GB-1 Growth Inhibition Assay IC50=0.02157 μM SANGER
RXF393 Growth Inhibition Assay IC50=0.02357 μM SANGER
LC-2-ad Growth Inhibition Assay IC50=0.02586 μM SANGER
KS-1 Growth Inhibition Assay IC50=0.0273 μM SANGER
ETK-1 Growth Inhibition Assay IC50=0.02832 μM SANGER
SW954 Growth Inhibition Assay IC50=0.02927 μM SANGER
Becker Growth Inhibition Assay IC50=0.03003 μM SANGER
MZ1-PC Growth Inhibition Assay IC50=0.03119 μM SANGER
ES6 Growth Inhibition Assay IC50=0.03193 μM SANGER
KURAMOCHI Growth Inhibition Assay IC50=0.03487 μM SANGER
CGTH-W-1 Growth Inhibition Assay IC50=0.03548 μM SANGER
VA-ES-BJ Growth Inhibition Assay IC50=0.03902 μM SANGER
LXF-289 Growth Inhibition Assay IC50=0.03956 μM SANGER
MPP-89 Growth Inhibition Assay IC50=0.04049 μM SANGER
SW872 Growth Inhibition Assay IC50=0.04161 μM SANGER
SNB75 Growth Inhibition Assay IC50=0.04435 μM SANGER
PSN1 Growth Inhibition Assay IC50=0.04474 μM SANGER
LB831-BLC Growth Inhibition Assay IC50=0.04609 μM SANGER
MFH-ino Growth Inhibition Assay IC50=0.04724 μM SANGER
TGBC24TKB Growth Inhibition Assay IC50=0.04761 μM SANGER
A388 Growth Inhibition Assay IC50=0.05095 μM SANGER
BB30-HNC Growth Inhibition Assay IC50=0.05437 μM SANGER
GI-ME-N Growth Inhibition Assay IC50=0.06118 μM SANGER
TGBC1TKB Growth Inhibition Assay IC50=0.06164 μM SANGER
TE-10 Growth Inhibition Assay IC50=0.06357 μM SANGER
A498 Growth Inhibition Assay IC50=0.07284 μM SANGER
TE-11 Growth Inhibition Assay IC50=0.07858 μM SANGER
BB65-RCC Growth Inhibition Assay IC50=0.08227 μM SANGER
C2BBe1 Growth Inhibition Assay IC50=0.08308 μM SANGER
NCI-H747 Growth Inhibition Assay IC50=0.08362 μM SANGER
IST-MES1 Growth Inhibition Assay IC50=0.08552 μM SANGER
KALS-1 Growth Inhibition Assay IC50=0.0949 μM SANGER
GCIY Growth Inhibition Assay IC50=0.09656 μM SANGER
RL95-2 Growth Inhibition Assay IC50=0.1038 μM SANGER
TE-1 Growth Inhibition Assay IC50=0.1054 μM SANGER
NCI-H1355 Growth Inhibition Assay IC50=0.11028 μM SANGER
SW962 Growth Inhibition Assay IC50=0.11292 μM SANGER
KLE Growth Inhibition Assay IC50=0.11317 μM SANGER
MC116 Growth Inhibition Assay IC50=0.1141 μM SANGER
NMC-G1 Growth Inhibition Assay IC50=0.11606 μM SANGER
KU812 Growth Inhibition Assay IC50=0.11883 μM SANGER
COLO-829 Growth Inhibition Assay IC50=0.12213 μM SANGER
NTERA-S-cl-D1 Growth Inhibition Assay IC50=0.12283 μM SANGER
IST-MEL1 Growth Inhibition Assay IC50=0.1345 μM SANGER
MLMA Growth Inhibition Assay IC50=0.14032 μM SANGER
LS-123 Growth Inhibition Assay IC50=0.14064 μM SANGER
LB2518-MEL Growth Inhibition Assay IC50=0.14162 μM SANGER
NB69 Growth Inhibition Assay IC50=0.14436 μM SANGER
8-MG-BA Growth Inhibition Assay IC50=0.15458 μM SANGER
K5 Growth Inhibition Assay IC50=0.16489 μM SANGER
KINGS-1 Growth Inhibition Assay IC50=0.16666 μM SANGER
SF268 Growth Inhibition Assay IC50=0.17404 μM SANGER
PF-382 Growth Inhibition Assay IC50=0.17678 μM SANGER
SH-4 Growth Inhibition Assay IC50=0.18413 μM SANGER
NALM-6 Growth Inhibition Assay IC50=0.19295 μM SANGER
CP66-MEL Growth Inhibition Assay IC50=0.19531 μM SANGER
697 Growth Inhibition Assay IC50=0.19987 μM SANGER
CP67-MEL Growth Inhibition Assay IC50=0.20488 μM SANGER
DSH1 Growth Inhibition Assay IC50=0.24001 μM SANGER
HCE-4 Growth Inhibition Assay IC50=0.26439 μM SANGER
MZ2-MEL Growth Inhibition Assay IC50=0.28537 μM SANGER
BL-41 Growth Inhibition Assay IC50=0.29123 μM SANGER
HUTU-80 Growth Inhibition Assay IC50=0.3142 μM SANGER
LOXIMVI Growth Inhibition Assay IC50=0.31503 μM SANGER
no-10 Growth Inhibition Assay IC50=0.31931 μM SANGER
KARPAS-422 Growth Inhibition Assay IC50=0.33997 μM SANGER
SW684 Growth Inhibition Assay IC50=0.3498 μM SANGER
SF126 Growth Inhibition Assay IC50=0.3541 μM SANGER
D-263MG Growth Inhibition Assay IC50=0.36224 μM SANGER
OVCAR-4 Growth Inhibition Assay IC50=0.37433 μM SANGER
BB49-HNC Growth Inhibition Assay IC50=0.38599 μM SANGER
ONS-76 Growth Inhibition Assay IC50=0.42951 μM SANGER
MZ7-mel Growth Inhibition Assay IC50=0.47911 μM SANGER
RCC10RGB Growth Inhibition Assay IC50=0.4911 μM SANGER
BOKU Growth Inhibition Assay IC50=0.49133 μM SANGER
no-11 Growth Inhibition Assay IC50=0.50228 μM SANGER
IST-SL2 Growth Inhibition Assay IC50=0.50302 μM SANGER
RKO Growth Inhibition Assay IC50=0.52966 μM SANGER
HT-144 Growth Inhibition Assay IC50=0.53609 μM SANGER
NCI-H446 Growth Inhibition Assay IC50=0.6276 μM SANGER
QIMR-WIL Growth Inhibition Assay IC50=0.70629 μM SANGER
MHH-PREB-1 Growth Inhibition Assay IC50=0.74469 μM SANGER
EW-16 Growth Inhibition Assay IC50=0.76178 μM SANGER
EW-24 Growth Inhibition Assay IC50=0.78165 μM SANGER
LB373-MEL-D Growth Inhibition Assay IC50=0.82508 μM SANGER
TE-9 Growth Inhibition Assay IC50=0.87532 μM SANGER
A3-KAW Growth Inhibition Assay IC50=0.98452 μM SANGER
A101D Growth Inhibition Assay IC50=1.03043 μM SANGER
OCUB-M Growth Inhibition Assay IC50=1.04412 μM SANGER
ES4 Growth Inhibition Assay IC50=1.05145 μM SANGER
TE-6 Growth Inhibition Assay IC50=1.21226 μM SANGER
D-502MG Growth Inhibition Assay IC50=1.23376 μM SANGER
KNS-42 Growth Inhibition Assay IC50=1.24412 μM SANGER
SNU-C2B Growth Inhibition Assay IC50=1.30589 μM SANGER
NCI-H1838 Growth Inhibition Assay IC50=1.30733 μM SANGER
NKM-1 Growth Inhibition Assay IC50=1.30859 μM SANGER
GI-1 Growth Inhibition Assay IC50=1.3622 μM SANGER
NB5 Growth Inhibition Assay IC50=1.39827 μM SANGER
CAS-1 Growth Inhibition Assay IC50=1.40992 μM SANGER
HCE-T Growth Inhibition Assay IC50=1.56714 μM SANGER
SBC-1 Growth Inhibition Assay IC50=1.57984 μM SANGER
JiyoyeP-2003 Growth Inhibition Assay IC50=1.73466 μM SANGER
TE-5 Growth Inhibition Assay IC50=1.79139 μM SANGER
CAN Growth Inhibition Assay IC50=1.82252 μM SANGER
SK-UT-1 Growth Inhibition Assay IC50=2.16693 μM SANGER
JVM-2 Growth Inhibition Assay IC50=2.36284 μM SANGER
LB771-HNC Growth Inhibition Assay IC50=2.57551 μM SANGER
NCCIT Growth Inhibition Assay IC50=2.86616 μM SANGER
NCI-H2126 Growth Inhibition Assay IC50=2.87552 μM SANGER
Calu-6 Growth Inhibition Assay IC50=3.05741 μM SANGER
SK-LMS-1 Growth Inhibition Assay IC50=3.11886 μM SANGER
ARH-77 Growth Inhibition Assay IC50=3.46915 μM SANGER
NB17 Growth Inhibition Assay IC50=3.63847 μM SANGER
A253 Growth Inhibition Assay IC50=3.73246 μM SANGER
OPM-2 Growth Inhibition Assay IC50=4.27685 μM SANGER
MV-4-11 Growth Inhibition Assay IC50=4.36454 μM SANGER
SR Growth Inhibition Assay IC50=4.49954 μM SANGER
KG-1 Growth Inhibition Assay IC50=4.60845 μM SANGER
OCI-AML2 Growth Inhibition Assay IC50=5.86154 μM SANGER
D-247MG Growth Inhibition Assay IC50=6.12519 μM SANGER
DJM-1 Growth Inhibition Assay IC50=6.48558 μM SANGER
RPMI-6666 Growth Inhibition Assay IC50=7.27067 μM SANGER
KARPAS-45 Growth Inhibition Assay IC50=7.51671 μM SANGER
LP-1 Growth Inhibition Assay IC50=7.54782 μM SANGER
RS4-11 Growth Inhibition Assay IC50=7.65787 μM SANGER
DU-4475 Growth Inhibition Assay IC50=8.21652 μM SANGER
MONO-MAC-6 Growth Inhibition Assay IC50=8.27066 μM SANGER
NCI-SNU-16 Growth Inhibition Assay IC50=8.56128 μM SANGER
SJSA-1 Growth Inhibition Assay IC50=8.72805 μM SANGER
MMAC-SF Growth Inhibition Assay IC50=8.79307 μM SANGER
SK-NEP-1 Growth Inhibition Assay IC50=8.89155 μM SANGER
J-RT3-T3-5 Growth Inhibition Assay IC50=8.96529 μM SANGER
SKM-1 Growth Inhibition Assay IC50=9.01734 μM SANGER
LB2241-RCC Growth Inhibition Assay IC50=9.02012 μM SANGER
SIG-M5 Growth Inhibition Assay IC50=9.02493 μM SANGER
EVSA-T Growth Inhibition Assay IC50=9.27793 μM SANGER
GT3TKB Growth Inhibition Assay IC50=9.35546 μM SANGER
NB6 Growth Inhibition Assay IC50=9.92259 μM SANGER
EHEB Growth Inhibition Assay IC50=10.0656 μM SANGER
HEL Growth Inhibition Assay IC50=10.4776 μM SANGER
ALL-PO Growth Inhibition Assay IC50=10.7938 μM SANGER
TGW Growth Inhibition Assay IC50=11.2828 μM SANGER
BC-3 Growth Inhibition Assay IC50=12.1138 μM SANGER
IA-LM Growth Inhibition Assay IC50=12.4445 μM SANGER
UACC-257 Growth Inhibition Assay IC50=12.9198 μM SANGER
KP-N-YS Growth Inhibition Assay IC50=12.9283 μM SANGER
Raji Growth Inhibition Assay IC50=13.7497 μM SANGER
SF539 Growth Inhibition Assay IC50=13.8557 μM SANGER
DMS-153 Growth Inhibition Assay IC50=14.0028 μM SANGER
L-540 Growth Inhibition Assay IC50=15.0672 μM SANGER
MN-60 Growth Inhibition Assay IC50=15.1979 μM SANGER
RPMI-8866 Growth Inhibition Assay IC50=17.4454 μM SANGER
NCI-H510A Growth Inhibition Assay IC50=19.3973 μM SANGER
NB13 Growth Inhibition Assay IC50=19.4877 μM SANGER
HAL-01 Growth Inhibition Assay IC50=19.7543 μM SANGER
NCI-H720 Growth Inhibition Assay IC50=20.2733 μM SANGER
REH Growth Inhibition Assay IC50=20.6357 μM SANGER
KNS-81-FD Growth Inhibition Assay IC50=23.146 μM SANGER
HC-1 Growth Inhibition Assay IC50=24.5551 μM SANGER
NCI-H2141 Growth Inhibition Assay IC50=24.7754 μM SANGER
MOLT-4 Growth Inhibition Assay IC50=26.6753 μM SANGER
OMC-1 Growth Inhibition Assay IC50=27.1422 μM SANGER
LC-1F Growth Inhibition Assay IC50=27.3245 μM SANGER
NCI-H1304 Growth Inhibition Assay IC50=28.1628 μM SANGER
BC-1 Growth Inhibition Assay IC50=28.651 μM SANGER
NCI-H64 Growth Inhibition Assay IC50=29.6253 μM SANGER
MOLT-16 Growth Inhibition Assay IC50=29.6292 μM SANGER
U-87-MG Growth Inhibition Assay IC50=30.766 μM SANGER
GAK Growth Inhibition Assay IC50=31.2686 μM SANGER
ES8 Growth Inhibition Assay IC50=32.1252 μM SANGER
HCC1599 Growth Inhibition Assay IC50=32.3325 μM SANGER
EB-3 Growth Inhibition Assay IC50=34.3117 μM SANGER
HCC1187 Growth Inhibition Assay IC50=35.8052 μM SANGER
SK-PN-DW Growth Inhibition Assay IC50=36.1943 μM SANGER
JVM-3 Growth Inhibition Assay IC50=37.2338 μM SANGER
HCC2157 Growth Inhibition Assay IC50=37.9946 μM SANGER
A4-Fuk Growth Inhibition Assay IC50=38.1009 μM SANGER
COR-L279 Growth Inhibition Assay IC50=40.2851 μM SANGER
DEL Growth Inhibition Assay IC50=41.9086 μM SANGER
NCI-H1395 Growth Inhibition Assay IC50=42.0163 μM SANGER
MHH-NB-11 Growth Inhibition Assay IC50=43.0818 μM SANGER
NCI-H2107 Growth Inhibition Assay IC50=43.4846 μM SANGER
NEC8 Growth Inhibition Assay IC50=44.336 μM SANGER
COLO-684 Growth Inhibition Assay IC50=46.2258 μM SANGER
LS-411N Growth Inhibition Assay IC50=48.4748 μM SANGER
Click to View More Cell Line Experimental Data

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.
Targets
LCK [1] Abl [1]
(Cell-free assay)		 Src [1]
(Cell-free assay)		 c-Kit (D816V) [2]
(Cell-free assay)		 c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro
In vitro Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]
Kinase Assay Kinase autophosphorylation assays
Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research Cell lines Ba/F3 cell lines
Concentrations ~32 nM
Incubation Time 72 hours
Method

Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.
Experimental Result Images Methods Biomarkers Images PMID
Western blot phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416) p27 / p21 p-FAK / p-STAT3 cleaved caspase 3 23049975
Growth inhibition assay IC50 23721490
Immunofluorescence SRC / Met F-actin / Actinin-4 / Paxillin α-tubulin 26517812
ELISA TNF-α E-selectin VCAM-1 17684099
In Vivo
In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]
Animal Research Animal Models EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
Dosages 30 mg/kg
Administration Administered via i.p.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05527418 Not yet recruiting Recent HIV-1 Infection Eva Bonfill|Institut d''Investigacions Biomèdiques August Pi i Sunyer November 2023 Phase 2
NCT05993949 Recruiting Lymphoblastic Leukemia Stanford University|Kite Pharma October 2 2023 Phase 1
NCT05780073 Recruiting HIV Infection Primary Fundació Institut Germans Trias i Pujol|Fundación FLS de Lucha Contra el Sida Enfermedades Infecciosas y Promoción de la Salud y Ciencia|Spanish Clinical Research Network - SCReN|IrsiCaixa|University of Turin Italy|Instituto de Salud Carlos III|Germans Trias i Pujol Hospital October 16 2023 Phase 2
NCT05198843 Terminated Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Inflammatory Carcinoma National Cancer Institute (NCI) November 8 2022 Phase 1|Phase 2
NCT04925648 Recruiting Metastatic Prostate Cancer St Vincent''s Hospital Sydney October 18 2021 Phase 2

Chemical lnformation & Solubility

Molecular Weight 488.01 Formula

C22H26ClN7O2S
CAS No. 302962-49-8 SDF Download Dasatinib SDF
Smiles CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 98 mg/mL ( (200.81 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

Answer:
Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

Question 2:
Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

Answer:
Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor